What vaccinations are recommended for a 36-year-old male living with Human Immunodeficiency Virus (HIV) on Dolutegravir (DTG)/Lamivudine (3TC) with an undetectable viral load and a CD4+ T-cell count of 621 cells/µL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Vaccination Schedule for a 36-Year-Old Male Living with HIV

For a 36-year-old male living with HIV on DTG/3TC with undetectable viral load and CD4+ count of 621 cells/µL, a comprehensive vaccination schedule is recommended to prevent opportunistic infections and maintain optimal health.

Immediate Vaccinations (Now)

Vaccine Dosing Schedule Notes
Influenza (inactivated) 1 dose annually Strong recommendation with high evidence [1,2]
Pneumococcal (PCV15/PCV20/PCV21) 1 dose now If PCV15 is used, follow with PPSV23 in 8 weeks [1,2]
Tdap 1 dose now If no adult dose previously received [1,2]
Hepatitis B 3-dose series (0,1,6 months) Consider high-dose (40 μg) formulation; check anti-HBs 1-2 months after completion [1,2]
HPV (if not previously received) 3-dose series (0,1-2,6 months) Recommended for ages 11-26 years, but can consider for this patient [1,2]
Hepatitis A 2-dose series (0,6-12 months) If no evidence of immunity [1,2]
Meningococcal (MenACWY) 2-dose primary series 2 months apart Booster dose every 5 years if risk continues [1,2]

Follow-up Vaccinations

Vaccine Timing Notes
PPSV23 (if PCV15 given) 8 weeks after PCV15 Second dose of PPSV23 5 years after first dose [1,2]
Td booster Every 10 years Following initial Tdap [2]
MMR Consider 2 doses 4 weeks apart Only if no evidence of immunity; safe with CD4 >200 cells/μL [1,2]
Varicella Consider 2 doses 3 months apart Only if no evidence of immunity; safe with CD4 >200 cells/μL [1,2]

Key Considerations

  1. CD4 Count and Live Vaccines: With a CD4 count of 621 cells/μL, this patient can safely receive live vaccines (MMR, varicella) if there's no evidence of immunity 1, 2.

  2. Pneumococcal Vaccination: HIV-infected individuals have 122 times higher risk of invasive pneumococcal disease compared to those without HIV 2. The newest recommendation is to use PCV15, PCV20, or PCV21, with PCV20 or PCV21 not requiring follow-up PPSV23 2.

  3. Hepatitis B Response: Check anti-HBs 1-2 months after completing the hepatitis B series. If <10 mIU/mL, administer a second series, preferably with high-dose formulation 1, 2.

  4. Previous Vaccination History: Since the patient completed Mexican childhood vaccinations up to age 12 (1999), he likely received some basic vaccines but may need updates according to current recommendations for HIV-infected adults 1.

  5. Contraindications: Live attenuated influenza vaccine (LAIV) is contraindicated in HIV-infected individuals, regardless of CD4 count 1, 2.

Vaccination Administration Tips

  • Multiple inactivated vaccines can be administered at the same visit 2.
  • Live vaccines (MMR, varicella) should be given on the same day or separated by at least 4 weeks 2.
  • For travel to endemic areas, yellow fever vaccine can be considered if CD4+ count remains ≥200 cells/mm³ 1, 2.

Common Pitfalls to Avoid

  1. Delaying pneumococcal vaccination can increase the risk of invasive pneumococcal disease 2.
  2. Incorrect sequencing of pneumococcal vaccines can result in hyporesponsiveness 2.
  3. Administering live vaccines to patients with CD4 counts <200 cells/mm³ can be dangerous 1, 2.
  4. Not checking hepatitis B antibody response after vaccination series can miss non-responders who need revaccination 1, 2.
  5. Assuming childhood vaccinations are sufficient without considering the need for boosters and HIV-specific recommendations 1, 2.

This vaccination schedule prioritizes preventing infections that could cause significant morbidity and mortality in people living with HIV, while taking advantage of the patient's good immune status (CD4 >500 cells/μL and undetectable viral load).

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Vaccination Guidelines for Immunocompromised Individuals

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.